Can Regeneron’s Odronextamab Stand Out With Better Safety?

Entering Crowded CD20 Bispecific Field

 
• By Alaric DeArment
  
The Regeneron, Genentech and AbbVie booths at the 2023 ASH conference • Source: Scrip
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer